IPO Issue Details
Issue Price / Price Band₹124 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size1,000 Shares per Lot
Total Issue Size23,50,000 shares (agg. up to ₹29 Cr)
Issue TypeBookbuilding IPO
Sale Type / CategoryFresh capital only
Exchange / PlatformBSE SME
IPO TypeSME
Subscription OpenFri, 20 Mar 2026
Subscription CloseTue, 24 Mar 2026
Anchor AllotmentThu, 19 Mar 2026
Basis of AllotmentWed, 25 Mar 2026
Initiation of RefundsFri, 27 Mar 2026
Credit of Shares to DematFri, 27 Mar 2026
Listing DateMon, 30 Mar 2026
UPI Mandate Deadline5:00 PM on 24 Mar 2026 (Day 3)
Application & Investment Details
Retail — Min (2 Lots)₹2,48,000 — 2,000 shares
Retail — Max (13 Lots)₹1,612,000 (13 Lots)
HNI — Min (3 Lots)₹3,72,000 — 3,000 shares
EPS (Pre-IPO)₹13.38
EPS (Post-IPO)₹11.82
P/E Ratio (Pre-IPO)9.27x
P/E Ratio (Post-IPO)10.49x
Net Offer to Public22,00,000 shares (agg. up to ₹27 Cr)
Reserved for Market Maker1,50,000 shares (agg. up to ₹2 Cr)
Pre-IPO Promoter Holding64,35,796 shares
Post-IPO Promoter Holding87,85,796 shares
About Speciality Medicines Ltd
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets.Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide.Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like:OncologyImmunologyNeurologyRare DiseasesAdditionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS.Global Expansion and RegistrationsAs of July 31, 2024, Speciality Medicines Limited has:1 plasma product registered in Bolivia127 products under registration across 8 countriesAs of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.
Shareholding & Lock-in
Pre-IPO Promoter Holding
64,35,796 shares
Post-IPO Promoter Holding
87,85,796 shares
⏳ Subscription opens on 20 Mar 2026, Fri
IPO Subscription Status
Subscription opens on 20 Mar 2026, Fri
Apply via ASBA or UPI on 20 Mar 2026
Open Date
20 Mar 2026
Fri
Close Date
24 Mar 2026
Tue
Allotment
25 Mar 2026
Wed
UPI Mandate Deadline: 5:00 PM on 24 Mar 2026 (Day 3)
Important Dates
Subscription OpensFri, 20 Mar 2026
Subscription ClosesTue, 24 Mar 2026
Anchor AllotmentThu, 19 Mar 2026
Basis of AllotmentWed, 25 Mar 2026
Initiation of RefundFri, 27 Mar 2026
Demat CreditFri, 27 Mar 2026
Listing DateMon, 30 Mar 2026
UPI Mandate Deadline5:00 PM on 24 Mar 2026 (Day 3)
Lot Size & Investment Table
| Application | Lots | Shares | Amount |
|---|
| Retail (Min — 2 Lots) |
2 |
2,000 |
₹248,000 |
| Retail (Max — 13 Lots) |
13 |
13,000 |
₹1,612,000 |
| S-HNI (Min — 14 Lots) |
14 |
14,000 |
₹1,736,000 |
| S-HNI (Max — 66 Lots) |
66 |
66,000 |
₹8,184,000 |
| B-HNI (Min — 67 Lots) |
67 |
67,000 |
₹8,308,000 |
* Issue Price ₹124 × Lot Size 1,000 shares
Company Financials — Restated Consolidated
(Amount in ₹ Crore)
| Particulars |
31 Oct 2025 |
31 Mar 2025 |
31 Mar 2024 |
| Revenue from Operations |
36.93 |
58.54 |
27.66 |
| EBITDA |
6.51 |
9.09 |
5.26 |
| Profit After Tax (PAT) |
6.06 |
8.61 |
2.93 |
| Net Worth |
36.47 |
30.42 |
15.06 |
| Total Assets |
45.57 |
39.98 |
22.68 |
| Reserves & Surplus |
30.04 |
23.98 |
9.95 |
| Total Borrowings |
4.81 |
5.05 |
2.86 |
| EBITDA Margin (%) |
17.73% |
— | — |
| PAT Margin (%) |
16.49% |
— | — |
Key Ratios & Valuation
Issue Price₹124
Face Value₹10 Per Share
Price / Book Value (P/BV)2.19
Return on Equity (RoE)18.11%
Return on Capital Employed (RoCE)16.68%
Return on Net Worth (RoNW)16.61%
PAT Margin (%)16.49%
EBITDA Margin (%)17.73%
Debt / Equity Ratio0.13
Issue Structure & Shareholding
Total Shares OfferedNot Available
Net Offer to Public22,00,000 shares (agg. up to ₹27 Cr)
Reserved for Market Maker1,50,000 shares (agg. up to ₹2 Cr)
Pre-Issue Promoter Holding64,35,796 shares
Post-Issue Promoter Holding87,85,796 shares
Script CodeNot Available
Objects of the Issue
Speciality Medicines Ltd proposes to utilize the net proceeds raised through this IPO for the following objects as stated in the Draft Red Herring Prospectus (DRHP) filed with SEBI:
Issue Composition & Shareholding
Issue TypeBookbuilding IPO
Sale TypeFresh capital only
Total Shares OfferedNot Available
Net Offer to Public22,00,000 shares (agg. up to ₹27 Cr)
Reserved for Market Maker1,50,000 shares (agg. up to ₹2 Cr)
Pre-Issue Promoter Holding64,35,796 shares
Post-Issue Promoter Holding87,85,796 shares
